Compare Expensify Inc (EXFY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs TransMedics Group Inc — how do they compare? Expensify Inc trades at $2.27 (market cap $209.73M), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 14.8× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | TMDX | |
|---|---|---|
Market Cap | $209.73M | $3.10B |
Sector | Technology | Technology |
52-Week High | $2.69 | $150.42 |
52-Week Low | $0.75 | $61.99 |
Enterprise Value | $149.35M | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.22, down 10.12% in the past 24 hours, with a bullish technical signal from moving averages and a neutral RSI. Recent Q2 2026 earnings showed a beat on EPS and a return to non-GAAP profitability, with revenue of $33.9 million. The company is expanding its AI-native solutions and European card offerings, supported by positive cash flow trends.
Outlook is cautiously optimistic due to earnings improvements and strategic expansions, but risks include persistent net losses, high P/E ratio of 258.82, and competitive pressures in expense management software. Analyst consensus is mixed with 44% buy ratings.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
